Publications by authors named "Jan Fourie"

Claim this Profile
P
Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
Johan Lombaard, Francis Ssali, Puthanakit Thanyawee, Jan Fourie, Simon Vanveggel

Antimicrob Agents Chemother· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.
Carlo Giaquinto, Muthuhadini Patience Mawela, Kulkanya Chokephaibulkit, Marinella Della Negra, Ismail Haroon Mitha, Jan Fourie

Pediatr Infect Dis J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Jacob P Lalezari, Gulam H Latiff, Cynthia Brinson, Juan Echevarría, Sandra Treviño-Pérez, Jan Fourie

Lancet HIV· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Pedro Cahn, Anton L Pozniak, Horacio Mingrone, Andrey Shuldyakov, Carlos Brites, Jan Fourie

Lancet· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Calvin J Cohen, Jean-Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie

J Acquir Immune Defic Syndr· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.
Jan Fourie, Jason Flamm, Amalia Rodriguez-French, Don Kilby, Pere Domingo

HIV Clin Trials· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Calvin J Cohen, Jaime Andrade-Villanueva, Bonaventura Clotet, Jan Fourie, Margaret A Johnson

Lancet· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Pedro Cahn, Jan Fourie, Beatriz Grinsztejn, Sally Hodder, Jean-Michel Molina

AIDS· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety (SMiLES).
José A Vazquez, Lauren L Patton, Joel B Epstein, Padaruth Ramlachan, Ismail Mitha, Jan Fourie

HIV Clin Trials· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Roberto Ortiz, Edwin Dejesus, Homayoon Khanlou, Evgeniy Voronin, Jan van Lunzen, Jan Fourie

AIDS· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis